Insulin Glulisine
- Generic Name
- Insulin Glulisine
- Brand Names
- Apidra
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 207748-29-6
- Unique Ingredient Identifier
- 7XIY785AZD
- Background
Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insul...
- Indication
用于治疗成人糖尿病。
- Associated Conditions
- Diabetes Mellitus, Type 1 Diabetes Mellitus, Hyperglycemia during critical illness
- Associated Therapies
- -
Insulin Glulisine in Type 1 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-02-28
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00297583
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00290927
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2009-08-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 250
- Registration Number
- NCT00290979
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Glulisine Pre- and Postmeal
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2010-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT00290043
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
- Conditions
- Interventions
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 390
- Registration Number
- NCT00283049
- Locations
- 🇺🇸
sanofi-aventis, US, Bridgewater, New Jersey, United States
ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 352
- Registration Number
- NCT00272064
- Locations
- 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy
OPAL - Insulin Glulisine, Diabetes Mellitus
- Conditions
- First Posted Date
- 2006-01-04
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 396
- Registration Number
- NCT00272012
- Locations
- 🇩🇪
Sanofi-Aventis, Berlin, Germany
Insulin Glulisine in Diabetes Mellitus, Type 2
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 311
- Registration Number
- NCT00174668
- Locations
- 🇷🇴
Sanofi-aventis, Bucharest, Romania
🇬🇧Sanofi-Aventis, Guildford, United Kingdom
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 811
- Registration Number
- NCT00174642
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford, United Kingdom
Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)
- Conditions
- Interventions
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2009-06-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 582
- Registration Number
- NCT00135941
- Locations
- 🇺🇸
Advanced Healthcare, Milwaukee, Wisconsin, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.